Padcev, the first targeted antibody-drug conjugate (ADC) for urothelial cancer, is attempting reimbursement in Korea.

According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for its Padcev (enfortumab vedotin), its antibody-drug conjugate (ADC) that is directed against Nectin-4.

The drug is recommended as Category 1 in the National Comprehensive Cancer Network (NCCN) guidelines. It is a new treatment option for urothelial cancer patients whose cancer has progressed or recurred even after receiving treatment with immunotherapy drugs and platinum-based chemotherapy, for whom no standard of care has existed as of yet.

The drug was a